Application of Ultrasound Integrated Precision Diagnosis Technology in Prevention of Kidney Disease and Its Progress
2 other identifiers
observational
208
1 country
2
Brief Summary
In this study, a prospective, randomized and controlled clinical study would be carried out to establish Ultrasound Integrated Precision Diagnosis Technology with elastography as the core technology to evaluate renal injury and repair comprehensively and accurately, and to improve the clinical diagnosis chance of renal injury (or renal fibrosis). Combined with the dynamic changes of biomarkers (inflammatory factors, cytokines secreted by immune cells, etc.) after kidney injury, the research on the prognosis of kidney disease with ultrasound elastography technology as the core would be explored, which aims to provide a scientific basis for the application of Ultrasound Integrated Precision Diagnosis Technology.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2019
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 29, 2019
CompletedFirst Submitted
Initial submission to the registry
August 1, 2019
CompletedFirst Posted
Study publicly available on registry
August 5, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 29, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2021
CompletedNovember 27, 2023
November 1, 2023
2.1 years
August 1, 2019
November 23, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Number of patients with creatinine increasing by more than 50%
Number of patients with creatinine increasing by more than 50% of baseline.
1st month-12 month
Number of patients with initiation of continuous renal replacement therapy
for non-transplantation patient
1st month-12 month
Rate of death
for all patients
1st month-12 month
Secondary Outcomes (3)
Number of patients with cardiovascular events
1st month-12 month
Number of patients with cerebrovascular events
1st month-12 month
Number of patients with new serious infections requiring hospitalization
1st month-12 month
Other Outcomes (2)
Number of patients with recovery of creatinine within 7 days less than 70%.
1st month-12 month
Number of patients with allograft loss
1st month-12 month
Study Arms (3)
A on C group
Acute on Chronic Kidney Disease patients
functional delayed graft function group
patients with functional delayed graft function(fDGF) after kidney transplantation
Normal
without functional kidney injury
Interventions
Compare the ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography) with the diagnostic gold standard of kidney disease---kidney biopsy
Eligibility Criteria
For A on C group:18-70 years old patient who can cooperate with breath-holding, breath-holding and breath-exhaling movements, and communicate without obstacles, signed informed consent and with abnormal renal pathology or glomerular filtration rate(GFR) (15 \<GFR\<90 ml/min.1.73 m2) or proteinuria \> 1 g/24 h due to any cause. For fDGF in kidney transplantation patient :18-65 years old patient who can cooperate with breath-holding, breath-holding and breath-exhaling movements, and communicate without obstacles, signed informed consent and received Kidney transplant recipients in our hospital from May 2019 to November 2019.
You may qualify if:
- for A on C group 1.18-70 years old; gender is not limited; 2. Patients who can cooperate with breath-holding, breath-holding and breath-exhaling movements, and communicate without obstacles.
- The informed consent has been signed; 4.Abnormal renal pathology or glomerular filtration rate(GFR) (15 \<GFR\<90 ml/min.1.73 m2) or proteinuria \> 1 g/24 h due to any cause.
- for kidney transplantation
- years old; gender is not limited;
- It can cooperate with breath-holding, breath-holding and breath-exhaling movements, and communicate without obstacles.
- The informed consent has been signed;
- Kidney transplant recipients in our hospital from May 2019 to November 2019
You may not qualify if:
- for A on C group
- Can't cooperate, can't lie down for at least 10 minutes, unconsciousness, severe hypoxia, restlessness need to rescue patients.
- Patients with pregnancy or cancer;
- There are other serious diseases that the researchers do not think it is suitable to participate in this experiment.
- Absolute contraindications of renal puncture, ① Obvious bleeding tendency; ②Severe hypertension (systolic pressure greater than 180 mm Hg or diastolic pressure greater than 115 mm Hg); ③Psychiatric patients or non-cooperating operators and isolated kidney (small kidney) Or relative contraindications of renal puncture: ① Active pyelonephritis, renal tuberculosis, hydronephrosis or pyonephrosis, ②renal abscess or perirenal abscess. ③Renal tumors or renal aneurysms. ④Polycystic kidney or renal cyst. ⑤Kidney position is too high (deep inhalation of the lower pole of the kidney is not below the twelve ribs) or migratory kidney. ⑥Obesity, severe ascites.
- b)for kidney transplantation
- <!-- -->
- Can't cooperate, can't lie down for at least 10 minutes, unconsciousness, severe hypoxia, restlessness need to rescue patients.
- Patients with pregnancy or cancer;
- There are other serious diseases that the researchers do not think it is suitable to participate in this experiment.
- Absolute contraindications of renal puncture, ① Obvious bleeding tendency; ②Severe hypertension (systolic pressure greater than 180 mm Hg or diastolic pressure greater than 115 mm Hg); ③Psychiatric patients or non-cooperating operators and isolated kidney (small kidney) Or relative contraindications of renal puncture: ① Active pyelonephritis, renal tuberculosis, hydronephrosis or pyonephrosis, ②renal abscess or perirenal abscess. ③Renal tumors or renal aneurysms. ④Polycystic kidney or renal cyst. ⑤Kidney position is too high (deep inhalation of the lower pole of the kidney is not below the twelve ribs) or migratory kidney. ⑥Obesity, severe ascites.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- RenJi Hospitallead
- China-Japan Friendship Hospitalcollaborator
- Duke Universitycollaborator
Study Sites (2)
Department of nephrology , Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200127, China
China-Japan Friendship Hospital
Beijing, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 1, 2019
First Posted
August 5, 2019
Study Start
April 29, 2019
Primary Completion
May 29, 2021
Study Completion
June 30, 2021
Last Updated
November 27, 2023
Record last verified: 2023-11
Data Sharing
- IPD Sharing
- Will not share